Log in

NASDAQ:PIRSPieris Pharmaceuticals Stock Price, Forecast & News

$3.07
-0.05 (-1.60 %)
(As of 05/22/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.02
Now: $3.07
$3.15
50-Day Range
$2.06
MA: $2.64
$3.12
52-Week Range
$1.60
Now: $3.07
$6.04
Volume180,020 shs
Average Volume340,083 shs
Market Capitalization$160.62 million
P/E RatioN/A
Dividend YieldN/A
Beta1.43
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its lead respiratory program includes PRS-060, a drug candidate, which is in Phase I clinical trial that binds to IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immuno-oncology program comprises PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases. The company is also developing PRS-344, a bispecific anticalin-antibody fusion protein that is in preclinical stage for oncology diseases; and PRS-080, a polyethylene glycol conjugated anticalin protein that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc., as well as others; and non-strategic license or option agreements with Aska Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc., and Sanofi, as well as license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Read More
Pieris Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.42 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PIRS
CUSIPN/A
Phone857-246-8998

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$46.28 million
Book Value$0.95 per share

Profitability

Net Income$-25,470,000.00

Miscellaneous

Employees107
Market Cap$160.62 million
Next Earnings Date8/14/2020 (Estimated)
OptionableOptionable

Receive PIRS News and Ratings via Email

Sign-up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter.

Pieris Pharmaceuticals (NASDAQ:PIRS) Frequently Asked Questions

How has Pieris Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Pieris Pharmaceuticals' stock was trading at $2.23 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PIRS shares have increased by 37.7% and is now trading at $3.07. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Pieris Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pieris Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pieris Pharmaceuticals.

When is Pieris Pharmaceuticals' next earnings date?

Pieris Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Pieris Pharmaceuticals.

How were Pieris Pharmaceuticals' earnings last quarter?

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) posted its quarterly earnings results on Monday, May, 11th. The biotechnology company reported ($0.07) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.17) by $0.10. The biotechnology company had revenue of $13.26 million for the quarter, compared to analysts' expectations of $9.43 million. Pieris Pharmaceuticals had a negative return on equity of 61.01% and a negative net margin of 42.26%. View Pieris Pharmaceuticals' earnings history.

What price target have analysts set for PIRS?

3 brokers have issued 1-year price objectives for Pieris Pharmaceuticals' shares. Their forecasts range from $5.00 to $9.00. On average, they anticipate Pieris Pharmaceuticals' stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 128.0% from the stock's current price. View analysts' price targets for Pieris Pharmaceuticals.

Has Pieris Pharmaceuticals been receiving favorable news coverage?

Media headlines about PIRS stock have been trending very negative recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Pieris Pharmaceuticals earned a news sentiment score of -3.9 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutPieris Pharmaceuticals.

Who are some of Pieris Pharmaceuticals' key competitors?

What other stocks do shareholders of Pieris Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pieris Pharmaceuticals investors own include Sangamo Therapeutics (SGMO), TG Therapeutics (TGTX), Corbus Pharmaceuticals (CRBP), Crispr Therapeutics (CRSP), Verastem (VSTM), Amarin (AMRN), Anavex Life Sciences (AVXL), Agile Therapeutics (AGRX), Omeros (OMER) and Sorrento Therapeutics (SRNE).

Who are Pieris Pharmaceuticals' key executives?

Pieris Pharmaceuticals' management team includes the following people:
  • Mr. Stephen S. Yoder, CEO, Pres & Director (Age 43)
  • Dr. Allan Reine, Sr. VP, CFO & Treasurer (Age 44)
  • Dr. Louis A. Matis, Sr. VP & Chief Devel. Officer (Age 68)
  • Mr. Claus Schalper MBA, Co-Founder & Sr. Advisor
  • Maria Kelman, Director of Investor Relations

What is Pieris Pharmaceuticals' stock symbol?

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

Who are Pieris Pharmaceuticals' major shareholders?

Pieris Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.42%), Corriente Advisors LLC (3.41%), State Street Corp (1.77%), Geode Capital Management LLC (1.37%), Acadian Asset Management LLC (1.25%) and Citigroup Inc. (0.79%). Company insiders that own Pieris Pharmaceuticals stock include Bvf Partners L P/Il and Christopher P Kiritsy. View institutional ownership trends for Pieris Pharmaceuticals.

Which major investors are selling Pieris Pharmaceuticals stock?

PIRS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Nuveen Asset Management LLC, Two Sigma Investments LP, Deutsche Bank AG, State Street Corp, BlackRock Inc., GSA Capital Partners LLP, and Ensign Peak Advisors Inc. View insider buying and selling activity for Pieris Pharmaceuticals.

Which major investors are buying Pieris Pharmaceuticals stock?

PIRS stock was purchased by a variety of institutional investors in the last quarter, including Corriente Advisors LLC, Citigroup Inc., AQR Capital Management LLC, Sigma Planning Corp, Geode Capital Management LLC, Los Angeles Capital Management & Equity Research Inc., Acadian Asset Management LLC, and Squarepoint Ops LLC. View insider buying and selling activity for Pieris Pharmaceuticals.

How do I buy shares of Pieris Pharmaceuticals?

Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Pieris Pharmaceuticals' stock price today?

One share of PIRS stock can currently be purchased for approximately $3.07.

How big of a company is Pieris Pharmaceuticals?

Pieris Pharmaceuticals has a market capitalization of $160.62 million and generates $46.28 million in revenue each year. The biotechnology company earns $-25,470,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Pieris Pharmaceuticals employs 107 workers across the globe.

What is Pieris Pharmaceuticals' official website?

The official website for Pieris Pharmaceuticals is www.pieris.com.

How can I contact Pieris Pharmaceuticals?

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected]

This page was last updated on 5/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.